Company profile for AAVantgarde Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AAVantgarde Bio is a clinical-stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. This platform is being clinically validated in two Inherited Retinal Diseases; Usher1B and Stargardt disease, and the platform is expected to address the gene therapy cargo capacity ...
AAVantgarde Bio is a clinical-stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. This platform is being clinically validated in two Inherited Retinal Diseases; Usher1B and Stargardt disease, and the platform is expected to address the gene therapy cargo capacity limitations of AAV vectors therefore the future pipeline could extend into many disease areas.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Italy
Address
Address
Via Vincenzo Gioberti, 8 20123 Milano
Telephone
Telephone
+39 02 83991300
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/italian-biotech-aavantgarde-eyes-143m-series-b-fund-retinal-disease-gene-therapy-trials

FIERCE BIOTECH
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/07/3162919/0/en/AAVantgarde-announces-3-presentations-at-ESGCT-2025-annual-meeting.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/10/02/3160220/0/en/AAVantgarde-Announces-FDA-Orphan-Drug-Designation-and-UK-CTA-approval-for-AAVB-039-for-the-Treatment-of-Stargardt-Disease.html

GLOBENEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/09/05/3145199/0/en/AAVantgarde-presents-updated-positive-clinical-data-from-its-AAVB-081-program-for-Usher-1B-at-EURetina-2025.html

GLOBENEWSWIRE
05 Sep 2025

https://www.globenewswire.com/news-release/2025/08/28/3140658/0/en/AAVantgarde-to-Present-Updated-Clinical-Data-from-LUCE-1-Study-at-EURetina-2025.html

GLOBENEWSWIRE
28 Aug 2025

https://www.globenewswire.com/news-release/2025/08/12/3131528/0/en/AAVantgarde-Bio-Announces-FDA-Fast-Track-Designation-for-AAVB-039-for-the-Treatment-of-Stargardt-Disease.html

GLOBENEWSWIRE
12 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty